Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point
Sustained investor interest in the diagnostics industry in light of the continuing COVID-19 pandemic drove initial public offerings in the Dx space in 2021, leading to more than three times as many IPOs in the space last year as in 2020.
Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point
Published in 360Dx
Author: Kelsy Ketchum and Craig Steger
Abstract:
Sustained investor interest in the diagnostics industry in light of the continuing COVID-19 pandemic drove initial public offerings in the Dx space in 2021, leading to more than three times as many IPOs in the space last year as in 2020.
News
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read the full article from Life Science Magazine here: Read More
Read MoreResources
Outcome Capital Life Sciences Pulse, March 2024
Outcome Capital Life Science Market Pulse March 2024 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
